A novel murine model of fetal and neonatal alloimmune thrombocytopenia: Response to intravenous IgG therapy

Blood

Volumn 107, Issue 7, 2006, Pages 2976-2983

  Ni, Heyu ^a   Chen, Pingguo ^b   Spring, Christopher M ^b   Sayeh, Ebrahim ^b   Semple, John W ^b   Lazarus, Alan H ^b   Hynes, Richard O ^b   Freedman, John ^b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA3 INTEGRIN; IMMUNOGLOBULIN G; MATERNAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; BLEEDING DISORDER; BRAIN HEMORRHAGE; CIRCULATION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; IMMUNE RESPONSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPONTANEOUS ABORTION; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION;

EID: 33645531319     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-06-2562     Document Type: Article

References (39)

1. Bussel J, Kaplan C. The fetal and neonatal consequences of maternal alloimmune thrombocytopenia. Baillieres Clin Haematol. 1998;11:391-408.
2. Dreyfus M, Kaplan C, Verdy E, Schlegel N, Durand-Zaleski I, Tchernia G. Frequency of immune thrombocytopenia in newborns: a prospective study: Immune Thrombocytopenia Working Group. Blood. 1997;89:4402-4406.
3. Bussel JB, Zabusky MR, Berkowitz RL, McFarland JG. Fetal alloimmune thrombocytopenia. N Engl J Med. 1997;337:22-26.
4. Metcalfe P, Watkins NA, Ouwehand WH, et al. Nomenclature of human platelet antigens. Vox Sang. 2003;85:240-245.
5. Williamson LM, Hackett G, Rennie J, et al. The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (PlA1, Zwa) as determined by antenatal screening. Blood. 1998;92:2280-2287.
6. Newman PJ, Valentin N. Human platelet alloantigens: recent findings, new perspectives. Thromb Haemost. 1995;74:234-239.
7. Akilesh S, Petkova S, Sproule TJ, Shaffer DJ, Christianson GJ, Roopenian D. The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. J Clin Invest. 2004;113:1328-1333.
8. Yoshida M, Claypool SM,Wagner JS, et al. Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity. 2004;20:769-783.
9. Hassan NM, Neiman RS. The pathology of the spleen in steroid-treated immune thrombocytopenic purpura. Am J Clin Pathol. 1985;84:433-438.
10. Kaplan C, Murphy MF, Kroll H, Waters AH. Feto-maternal alloimmune thrombocytopenia: antenatal therapy with IvIgG and steroids: more questions than answers: European Working Group on FMAIT. Br J Haematol. 1998;100:62-65.
11. Crow AR, Song S, Semple JW, Freedman J, Lazarus AH. IVIg inhibits reticuloendothelial system function and ameliorates murine passive-immune thrombocytopenia independent of antiidiotype reactivity. Br J Haematol. 2001;115:679-686.
12. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science. 2001;291:484-486.
13. Bayry J, Misra N, Latry V, et al. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Transfus Clin Biol. 2003;10:165-169.
14. Hodivala-Dilke KM, McHugh KP, Tsakiris DA, et al. Beta3-integrin- deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest. 1999;103:229-238.
15. Killie M HA, Kjeldsen-Kragh J, Skogen B. The natural course of anti-HPA 1a antibody levels in subsequent non-compatible pregnancies [abstract]. 8th European Symposium on Platelet and Granulocyte Immunobiology. Rust, Burgenland, Austria; 2004:COM16.
16. Malek A. Ex vivo human placenta models: transport of immunoglobulin G and its subclasses. Vaccine. 2003;21:3362-3364.
17. Oyaizu N, Yasumizu R, Miyama-Inaba M, et al. (NZW x BXSB)F1 mouse: a new animal model of idiopathic thrombocytopenic purpura. J Exp Med. 1988;167:2017-2022.
18. Dekel B, Marcus H, Shenkman B, et al. Human/BALB radiation chimera engrafted with splenocytes from patients with idiopathic thrombocytopenic purpura produce human platelet antibodies. Immunology. 1998;94:410-416.
19. Hansen RJ, Balthasar JP. Pharmacokinetics, pharmacodynamics, and platelet binding of an anti-glycoprotein IIb/IIIa monoclonal antibody (7E3) in the rat: a quantitative rat model of immune thrombocytopenic purpura. J Pharmacol Exp Ther. 2001;298:165-171.
20. Semple JW, Milev Y, Cosgrave D, et al. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood. 1996;87:4245-4254.
21. Panitsas FP, Theodoropoulou M, Kouraklis A, et al. Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood. 2004;103:2645-2647.
22. Aluvihare VR, Kallikourdis M, Betz AG. Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol. 2004;5:266-271.
23. Fusi FM, Tamburini C, Mangili F, Montesano M, Ferrari A, Bronson RA. The expression of alpha v, alpha 5, beta 1, and beta 3 integrin chains on ejaculated human spermatozoa varies with their functional state. Mol Hum Reprod. 1996;2:169-175.
24. Ghetie V, Ward ES. Multiple roles for the major histocompatibility complex class I- related receptor FcRn. Annu Rev Immunol. 2000;18:739-766.
25. Imbach P, Barandun S, Baumgartner C, Hirt A, Hofer F, Wagner HP. High-dose intravenous gammaglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood. Helv Paediatr Acta. 1981;36:81-86.
26. Berchtold P, McMillan R. Therapy of chronic idiopathic thrombocytopenic purpura in adults. Blood. 1989;74:2309-2317.
27. de Grandmont MJ, Racine C, Roy A, Lemieux R, Neron S. Intravenous immunoglobulins induce the in vitro differentiation of human B lymphocytes and the secretion of IgG. Blood. 2003;101:3065-3073.
28. Tsubakio T, Kurata Y, Katagiri S, et al. Alteration of T cell subsets and immunoglobulin synthesis in vitro during high dose gamma-globulin therapy in patients with idiopathic thrombocytopenic purpura. Clin Exp Immunol. 1983;53:697-702.
29. Macey MG, Newland AC. CD4 and CD8 subpopulation changes during high dose intravenous immunoglobulin treatment. Br J Haematol. 1990;76:513-520.
30. Bayry J, Lacroix-Desmazes S, Carbonneil C, et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood. 2003;101:758-765.
31. Ravetch JV, Lanier LL. Immune inhibitory receptors. Science. 2000;290:84-89.
32. Ghetie V, Ward ES. FcRn: the MHC class I-related receptor that is more than an IgG transporter. Immunol Today. 1997;18:592-598.
33. Antohe F, Radulescu L, Gafencu A, Ghetie V, Simionescu M. Expression of functionally active FcRn and the differentiated bidirectional transport of IgG in human placental endothelial cells. Hum Immunol. 2001;62:93-105.
34. Ahouse JJ, Hagerman CL, Mittal P, et al. Mouse MHC class I-like Fc receptor encoded outside the MHC. J Immunol. 1993;151:6076-6088.
35. Bleeker WK, Teeling JL, Hack CE. Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect. Blood. 2001;98:3136-3142.
36. Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med. 1999;340:227-228.
37. Hansen RJ, Balthasar JP. Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia. Blood. 2002;100:2087-2093.
38. Bowman J, Harman C, Mentigolou S, Pollock J. Intravenous fetal transfusion of immunoglobulin for alloimmune thrombocytopenia. Lancet. 1992;340:1034-1035.
39. Teeling JL, Jansen-Hendriks T, Kuijpers TW, et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood. 2001;98:1095-1099.